Literature DB >> 15556118

Bipolar disorder and substance abuse.

Frances R Levin1, Grace Hennessy.   

Abstract

Substance use disorders are overrepresented in individuals with bipolar and bipolar spectrum disorders. Although awareness of this phenomenon has increased over the past 20 years, few empirically based treatment strategies have been developed for this challenging patient population. This review examines the relationship between bipolar and substance use disorders and treatment options that have been studied in this patient population. First, we examine the high prevalence rates of substance use disorders in individuals diagnosed with bipolar disorder, the common problems associated with establishing a bipolar disorder diagnosis in individuals who abuse substances, the possible explanations for the frequent coexistence of bipolar and substance use disorders, and the negative effect of substance abuse on the course of and treatment outcomes for bipolar disorder. The review then focuses on treatment approaches for this patient population, including integrated group therapy for co-occurring bipolar and substance use disorders and pharmacotherapies that target both disorders. Finally, we present suggestions for medications that might be tested for their efficacy in treating both disorders in specific subgroups of patients with bipolar and substance use disorders.

Entities:  

Mesh:

Year:  2004        PMID: 15556118     DOI: 10.1016/j.biopsych.2004.05.008

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  31 in total

1.  Characterizing the longitudinal patterns of substance use among individuals diagnosed with serious mental illness after psychiatric hospitalization.

Authors:  Amber L Bahorik; Christina E Newhill; Shaun M Eack
Journal:  Addiction       Date:  2013-03-28       Impact factor: 6.526

Review 2.  Future pharmacological treatments for substance use disorders.

Authors:  Ariadna Forray; Mehmet Sofuoglu
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 3.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

4.  Interventions for Sleep Disturbance in Bipolar Disorder.

Authors:  Allison G Harvey; Katherine A Kaplan; Adriane M Soehner
Journal:  Sleep Med Clin       Date:  2015-03

5.  History of manic and hypomanic episodes and risk of incident cardiovascular disease: 11.5 year follow-up from the Baltimore Epidemiologic Catchment Area Study.

Authors:  Christine M Ramsey; Jeannie-Marie Leoutsakos; Lawrence S Mayer; William W Eaton; Hochang B Lee
Journal:  J Affect Disord       Date:  2010-06-08       Impact factor: 4.839

6.  Association between illicit drug and alcohol use and first manic episode.

Authors:  Ellen Frank; Elaine Boland; Danielle M Novick; Jacopo V Bizzarri; Paola Rucci
Journal:  Pharmacol Biochem Behav       Date:  2006-12-26       Impact factor: 3.533

7.  Improving treatment adherence in patients with bipolar disorder and substance abuse: rationale and initial development of a novel psychosocial approach.

Authors:  Brandon A Gaudiano; Lauren M Weinstock; Ivan W Miller
Journal:  J Psychiatr Pract       Date:  2011-01       Impact factor: 1.325

Review 8.  The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.

Authors:  David Mysels; Maria A Sullivan
Journal:  Am J Addict       Date:  2009 Jul-Aug

9.  Cognitive functioning in patients with bipolar disorder: association with depressive symptoms and alcohol use.

Authors:  Marieke J van der Werf-Eldering; Huibert Burger; Esther A E Holthausen; André Aleman; Willem A Nolen
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

10.  Demographic and clinical characteristics associated with comorbid cannabis use disorders (CUDs) in hospitalized patients with bipolar I disorder.

Authors:  Lauren M Weinstock; Brandon A Gaudiano; Susan J Wenze; Gary Epstein-Lubow; Ivan W Miller
Journal:  Compr Psychiatry       Date:  2015-10-23       Impact factor: 3.735

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.